Muses Labs Inc. has sold more than $2 million of a nearly $6 million equity offering, according to a filing with the Securities and Exchange Commission (SEC). The company has a “different approach to Alzheimer’s treatment.”

The Raleigh-based company has raised $2, 057, 477 of a $5.8 million offering from 21 investors according to the filingwith the SEC.

The company has developed a personalized Alzheimer’s treatment aimed at slowing or reversing cognitive decline using its MEND protocol. MEND stands for “metabolic enhancement for neuro-degeneration.”

The company says it has seen evidence of some improvement in Alzheimer’s patients. Carolina Partners CEO Stan Monroe told WRAL, “It gives an element of hope in a hopeless situation.

You can see a WRAL Heath Team report on the company here: